source
- Eli Lilly to seek approval next year for retatrutide after strong Phase 3 obesity resultsEli Lilly announced that its experimental obesity drug retatrutide will be submitted to regulators for approval early next year. The decision follows recent Phase 3 trial data that showed the drug…
- FDA advisory panel backs broader use of wellness peptide BPC-157 despite internal concernsThe FDA advisory committee voted Thursday to recommend loosening restrictions on BPC-157, a peptide popular among health and wellness enthusiasts for muscle repair, injury healing, metabolism suppo…